221 related articles for article (PubMed ID: 24297869)
1. A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites.
Haque JA; McDonald MG; Kulman JD; Rettie AE
Blood; 2014 Jan; 123(4):582-9. PubMed ID: 24297869
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells.
Tie JK; Jin DY; Tie K; Stafford DW
J Thromb Haemost; 2013 Aug; 11(8):1556-64. PubMed ID: 23710884
[TBL] [Abstract][Full Text] [Related]
3. Warfarin and vitamin K compete for binding to Phe55 in human VKOR.
Czogalla KJ; Biswas A; Höning K; Hornung V; Liphardt K; Watzka M; Oldenburg J
Nat Struct Mol Biol; 2017 Jan; 24(1):77-85. PubMed ID: 27941861
[TBL] [Abstract][Full Text] [Related]
4. Development of a sandwich enzyme-linked immunosorbent assay (ELISA) to quantify γ-glutamyl-carboxylated clotting factor IX and assess redox susceptibility of anticoagulant chemicals.
Sato R; Watanabe K; Kamata R; Takeda K
J Vet Med Sci; 2022 Jun; 84(6):804-808. PubMed ID: 35444089
[TBL] [Abstract][Full Text] [Related]
5. Combination index of the concentration and in vivo antagonism activity of racemic warfarin and its metabolites to assess individual drug responses.
Kobayashi S; Ishii K; Yamada Y; Ryu E; Hashizume J; Nose S; Hara T; Nakashima M; Ohyama K
J Thromb Thrombolysis; 2019 Apr; 47(3):467-472. PubMed ID: 30465164
[TBL] [Abstract][Full Text] [Related]
6. The characterization of potent novel warfarin analogs.
Kerr JS; Li HY; Wexler RS; Robinson AJ; Robinson CS; Boswell GA; Krauthauser C; Harlow PP
Thromb Res; 1997 Oct; 88(2):127-36. PubMed ID: 9361366
[TBL] [Abstract][Full Text] [Related]
7. Functional study of the vitamin K cycle in mammalian cells.
Tie JK; Jin DY; Straight DL; Stafford DW
Blood; 2011 Mar; 117(10):2967-74. PubMed ID: 21239697
[TBL] [Abstract][Full Text] [Related]
8. Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition.
Wu S; Chen X; Jin DY; Stafford DW; Pedersen LG; Tie JK
Blood; 2018 Aug; 132(6):647-657. PubMed ID: 29743176
[TBL] [Abstract][Full Text] [Related]
9. VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites.
Czogalla KJ; Liphardt K; Höning K; Hornung V; Biswas A; Watzka M; Oldenburg J
Blood Adv; 2018 Mar; 2(6):691-702. PubMed ID: 29581108
[TBL] [Abstract][Full Text] [Related]
10. Structural and cellular basis of vitamin K antagonism.
Liu S; Shen G; Li W
J Thromb Haemost; 2022 Sep; 20(9):1971-1983. PubMed ID: 35748323
[TBL] [Abstract][Full Text] [Related]
11. The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats.
Wajih N; Sane DC; Hutson SM; Wallin R
J Biol Chem; 2004 Jun; 279(24):25276-83. PubMed ID: 15075329
[TBL] [Abstract][Full Text] [Related]
12. Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase.
Rishavy MA; Hallgren KW; Wilson L; Singh S; Runge KW; Berkner KL
Blood; 2018 Jun; 131(25):2826-2835. PubMed ID: 29592891
[TBL] [Abstract][Full Text] [Related]
13. Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system.
Wajih N; Sane DC; Hutson SM; Wallin R
J Biol Chem; 2005 Mar; 280(11):10540-7. PubMed ID: 15640149
[TBL] [Abstract][Full Text] [Related]
14. Functional Study of the Vitamin K Cycle Enzymes in Live Cells.
Tie JK; Stafford DW
Methods Enzymol; 2017; 584():349-394. PubMed ID: 28065270
[TBL] [Abstract][Full Text] [Related]
15. VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy.
Hammed A; Matagrin B; Spohn G; Prouillac C; Benoit E; Lattard V
J Biol Chem; 2013 Oct; 288(40):28733-42. PubMed ID: 23928358
[TBL] [Abstract][Full Text] [Related]
16. Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane.
Cain D; Hutson SM; Wallin R
J Biol Chem; 1997 Nov; 272(46):29068-75. PubMed ID: 9360981
[TBL] [Abstract][Full Text] [Related]
17. Stabilization of warfarin-binding pocket of VKORC1 and VKORL1 by a peripheral region determines their different sensitivity to warfarin inhibition.
Shen G; Li S; Cui W; Liu S; Liu Q; Yang Y; Gross M; Li W
J Thromb Haemost; 2018 Jun; 16(6):1164-1175. PubMed ID: 29665197
[TBL] [Abstract][Full Text] [Related]
18. A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle.
Chen X; Li C; Jin DY; Ingram B; Hao Z; Bai X; Stafford DW; Hu K; Tie JK
Blood; 2020 Aug; 136(7):898-908. PubMed ID: 32374827
[TBL] [Abstract][Full Text] [Related]
19. Vitamin K epoxide reductase and its paralogous enzyme have different structures and functions.
Sinhadri BCS; Jin DY; Stafford DW; Tie JK
Sci Rep; 2017 Dec; 7(1):17632. PubMed ID: 29247216
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationships of novel warfarin derivatives.
Gebauer M
Bioorg Med Chem; 2007 Mar; 15(6):2414-20. PubMed ID: 17275317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
